This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
ABSTRACT
BACKGROUND: Cerebral aneurysm recurrence serves as a significant endpoint for assessing the efficacy of various endovascular treatment strategies. The impact of smoking on outcomes such as aneurysm occlusion, recurrence, and recanalization remains unclear due to conflicting evidence.
PURPOSE: To systematically evaluate the role of smoking in influencing angiographic outcomes following endovascular treatment of intracranial aneurysms.
DATA SOURCES: Comprehensive searches were conducted in PubMed, Embase, Scopus, and Web of Science
STUDY SELECTION: This systematic review and meta-analysis followed PRISMA guidelines to identify relevant studies assessing smoking's impact on intracranial aneurysms following endovascular treatment.
DATA ANALYSIS: Studies were screened, selected, and assessed for risk of bias using appropriate checklists. Data on complete and adequate aneurysm occlusion, and recurrence/recanalization rates were extracted. Random-effects meta-analyses calculated risk ratios (ORs) with 95% confidence intervals (CIs). Heterogeneity was measured using the I2 statistic.
DATA SYNTHESIS: A total of 26 studies, encompassing 6,031 patients, met the inclusion criteria. Smokers had higher rates of complete aneurysm occlusion (RR 1.12, 95% CI 1.06–1.19; p < 0.01). Subgroup analysis revealed that smokers undergoing flow diversion exhibited a higher rate of complete occlusion (RR 1.14, 95% CI 1.07–1.21; p < 0.01). However, for patients undergoing coiling, there was no significant difference in complete occlusion rates between smokers and non-smokers (RR 1.00, 95% CI 0.83– 1.20; p = 0.46). Recurrence/recanalization rates were similar between smokers and non-smokers: RR 1.17, 95% CI 0.93–1.47; p = 0.20, and the rate of aneurysm retreatment did not differ between the smokers and non-smokers: RR 0.82, 95% CI 0.59–1.13; p =0.23.
LIMITATIONS: Heterogeneity in definitions of smoking status, variations in follow-up durations, short follow up, retrospective nature of studies.
CONCLUSIONS: Smoking status does not significantly impact aneurysm recanalization or retreatment after endovascular repair. However, the impact of smoking on complete occlusion rate might differ based on the type of device used for treatment. Histological and molecular factors may contribute to varied outcomes, highlighting the necessity for further research to understand smoking's role in aneurysm healing. Clinically, patients should be advised about the risks of smoking, though current evidence suggests that smoking cessation may not consistently affect treatment efficacy.
ABBREVIATIONS: sAH = subarachnoid hemorrhage; RROC = Raymond-Roy occlusion classification.
Footnotes
Equal contribution
Disclosure of potential conflicts of interest: D.F.K. holds equity in Nested Knowledge, Superior Medical Editors, and Conway Medical, Marblehead Medical and Piraeus Medical. He receives grant support from MicroVention, Medtronic, Balt, and Insera Therapeutics; has served on the Data Safety Monitoring Board for Vesalio; and received royalties from Medtronic. R.K. has the following conflicts: Research support from: Cerenovus Inc, Medtronic, Endovascular Engineering, Frontior Bio, Sensome Inc, Endomimetics, Ancure LLC, Neurogami Medical, MIVI Biosciences, Monarch Biosciences, Stryker Inc, Conway Medical, Pireus Medical, and Bionaut Labs. He holds the following research grants Research Grants: NIH (R01NS076491, R44NS107111, R43NS110114 and R21NS128199) and NSF (081215707).
- © 2025 by American Journal of Neuroradiology